LENSAR® to Report First Quarter 2026 Results on May 8, 2026
Rhea-AI Summary
LENSAR (Nasdaq: LNSR) will report first quarter 2026 financial results before market open on Friday, May 8, 2026. Management will host a conference call and webcast at 8:30 am ET the same day to discuss results, corporate and operational highlights, and strategic initiatives.
Registration is required for telephone participation and the live webcast is available under Events & Presentations on the company investor relations website. A replay will be available through May 15, 2026.
Positive
- None.
Negative
- None.
News Market Reaction – LNSR
In the Apr 30 session, LNSR declined 2.97%, reflecting a moderate negative market reaction. Argus tracked a peak move of +4.2% during that session. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 31 | Earnings report | Positive | +1.5% | Reported Q4 and full-year 2025 results with stronger recurring revenue base. |
| Mar 16 | Merger termination | Negative | -32.9% | Alcon and LENSAR mutually ended merger after FTC opposition and review costs. |
| Mar 16 | Merger termination | Negative | -32.9% | LENSAR detailed termination of Alcon merger and retention of $10M deposit. |
| Feb 25 | Acquisition update | Neutral | -2.3% | Updated expected closing timing for Alcon acquisition amid ongoing FTC review. |
| Nov 06 | Earnings report | Neutral | -8.6% | Reported Q3 2025 results with modest revenue growth and higher SG&A expenses. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Large negative reactions followed merger-related setbacks, while earnings updates have produced more moderate moves in either direction.
Over the last six months, LNSR has navigated both operational updates and significant strategic shifts. On Nov 6, 2025, third-quarter 2025 earnings showed revenue growth but drew a -8.63% move. Fourth-quarter and full-year 2025 results on Mar 31, 2026 highlighted stronger recurring revenue and produced a modest +1.53% reaction. By contrast, news tied to the Alcon merger and its ultimate termination on Mar 16, 2026 triggered sharp declines of -32.85%. Today’s announcement simply sets the first-quarter 2026 earnings date and call details, continuing the cadence of regular financial communication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ORLANDO, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that the Company’s first quarter 2026 financial results will be released before market open on Friday, May 8, 2026. LENSAR’s management will host a conference call and webcast at 8:30 am ET on Friday, May 8, 2026 to discuss the results, recent corporate and operational highlights and provide an update on key strategic initiatives.
To participate by telephone, please use this registration link. All participants must use the link to complete the online registration process in advance of the conference call. The live webcast can be accessed under “Events & Presentations” in the Investor Relations section of the company’s website at https://ir.lensar.com. The call and webcast replay will be available until May 15, 2026.
About LENSAR
LENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. LENSAR has developed its ALLY Robotic Cataract Laser System™ as a compact, highly ergonomic system utilizing an extremely fast dual-modality laser and integrating AI into proprietary imaging and software. ALLY is designed to transform premium cataract surgery by utilizing LENSAR’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes LENSAR’s proprietary Streamline® software technology, designed to guide surgeons to achieve better outcomes.
| Contacts: | Lee Roth |
| Thomas R. Staab, II, CFO | Burns McClellan for LENSAR |
| ir.contact@lensar.com | lroth@burnsmc.com |
